BACKGROUND: Among community-dwelling older adults, frailty is associated with heightened markers of inflammation and subsequent mortality. Although frailty is common among end-stage renal disease (ESRD) patients, the role of frailty and markers of inflammation in this population remains unclear. We quantified these associations in patients on the kidney transplant waitlist and tested whether frailty and/or markers of inflammation improve waitlist mortality risk prediction. METHODS: We studied 1975 ESRD patients on the kidney transplant waitlist (November 1, 2009, to February 28, 2017) in a multi-center cohort study of frailty. Serum inflammatory markers (interleukin-6 [IL-6], soluble tumor necrosis factor-α receptor-1 [sTNFR1], and C-reactive protein [CRP]) were analyzed in 605 of these participants; we calculated the inflammatory index score using IL-6 and sTNFR1. We compared the C-statistic of an established registry-based prediction model for waitlist mortality adding frailty and/or inflammatory markers (1 SD change in log IL-6, sTNFR1, CRP, or inflammatory index). RESULTS: The registry-based model had moderate predictive ability (c-statistic = 0.655). Frailty was associated with increased mortality (2.19; 95% confidence interval [CI], 1.26-3.79) but did not improve risk prediction (c-statistic = 0.646; P = 0.65). Like frailty, IL-6 (2.13; 95% CI, 1.41-3.22), sTNFR1 (1.70; 95% CI, 1.12-2.59), CRP (1.68; 95% CI, 1.06-2.67), and the inflammatory index (2.09; 95% CI, 1.38-3.16) were associated with increased mortality risk; unlike frailty, adding IL-6 (c-statistic = 0.777; P = 0.02), CRP (c-statistic = 0.728; P = 0.02), or inflammatory index (c-statistic = 0.777; P = 0.02) substantially improved mortality risk prediction. CONCLUSIONS: Frailty and markers of inflammation were associated with increased waitlist mortality risk, but only markers of inflammation significantly improved ESRD risk prediction. These findings help clarify the accelerated aging physiology of ESRD and highlight easy-to-measure markers of increased waitlist mortality risk.
BACKGROUND: Among community-dwelling older adults, frailty is associated with heightened markers of inflammation and subsequent mortality. Although frailty is common among end-stage renal disease (ESRD) patients, the role of frailty and markers of inflammation in this population remains unclear. We quantified these associations in patients on the kidney transplant waitlist and tested whether frailty and/or markers of inflammation improve waitlist mortality risk prediction. METHODS: We studied 1975 ESRDpatients on the kidney transplant waitlist (November 1, 2009, to February 28, 2017) in a multi-center cohort study of frailty. Serum inflammatory markers (interleukin-6 [IL-6], soluble tumor necrosis factor-α receptor-1 [sTNFR1], and C-reactive protein [CRP]) were analyzed in 605 of these participants; we calculated the inflammatory index score using IL-6 and sTNFR1. We compared the C-statistic of an established registry-based prediction model for waitlist mortality adding frailty and/or inflammatory markers (1 SD change in log IL-6, sTNFR1, CRP, or inflammatory index). RESULTS: The registry-based model had moderate predictive ability (c-statistic = 0.655). Frailty was associated with increased mortality (2.19; 95% confidence interval [CI], 1.26-3.79) but did not improve risk prediction (c-statistic = 0.646; P = 0.65). Like frailty, IL-6 (2.13; 95% CI, 1.41-3.22), sTNFR1 (1.70; 95% CI, 1.12-2.59), CRP (1.68; 95% CI, 1.06-2.67), and the inflammatory index (2.09; 95% CI, 1.38-3.16) were associated with increased mortality risk; unlike frailty, adding IL-6 (c-statistic = 0.777; P = 0.02), CRP (c-statistic = 0.728; P = 0.02), or inflammatory index (c-statistic = 0.777; P = 0.02) substantially improved mortality risk prediction. CONCLUSIONS: Frailty and markers of inflammation were associated with increased waitlist mortality risk, but only markers of inflammation significantly improved ESRD risk prediction. These findings help clarify the accelerated aging physiology of ESRD and highlight easy-to-measure markers of increased waitlist mortality risk.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Kirsten L Johansen; Lorien S Dalrymple; Cynthia Delgado; Glenn M Chertow; Mark R Segal; Janet Chiang; Barbara Grimes; George A Kaysen Journal: Clin J Am Soc Nephrol Date: 2017-06-02 Impact factor: 8.237
Authors: Ronenn Roubenoff; Helen Parise; Hélène A Payette; Leslie W Abad; Ralph D'Agostino; Paul F Jacques; Peter W F Wilson; Charles A Dinarello; Tamara B Harris Journal: Am J Med Date: 2003-10-15 Impact factor: 4.965
Authors: M A McAdams-DeMarco; H Ying; I Olorundare; E A King; N Desai; N Dagher; B Lonze; R Montgomery; J Walston; D L Segev Journal: J Frailty Aging Date: 2016
Authors: Jeroen P Kooman; Natascha J H Broers; Len Usvyat; Stephan Thijssen; Frank M van der Sande; Tom Cornelis; Nathan W Levin; Karel M L Leunissen; Peter Kotanko Journal: Nephrol Dial Transplant Date: 2012-11-08 Impact factor: 5.992
Authors: Jon Kobashigawa; Darshana Dadhania; Sangeeta Bhorade; Deborah Adey; Joseph Berger; Geetha Bhat; Marie Budev; Andres Duarte-Rojo; Michael Dunn; Shelley Hall; Meera N Harhay; Kirsten L Johansen; Susan Joseph; Cassie C Kennedy; Evan Kransdorf; Krista L Lentine; Raymond J Lynch; Mara McAdams-DeMarco; Shunji Nagai; Michael Olymbios; Jignesh Patel; Sean Pinney; Joanna Schaenman; Dorry L Segev; Palak Shah; Lianne G Singer; Jonathan P Singer; Christopher Sonnenday; Puneeta Tandon; Elliot Tapper; Stefan G Tullius; Michael Wilson; Martin Zamora; Jennifer C Lai Journal: Am J Transplant Date: 2018-12-22 Impact factor: 8.086
Authors: María Pérez Fernández; Patricia Martínez Miguel; Hao Ying; Christine E Haugen; Nadia M Chu; Diego María Rodríguez Puyol; Leocadio Rodríguez-Mañas; Silas P Norman; Jeremy D Walston; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2019-01-09 Impact factor: 3.754
Authors: Alvin G Thomas; Jessica M Ruck; Ashton A Shaffer; Christine E Haugen; Hao Ying; Fatima Warsame; Nadia Chu; Michelle C Carlson; Alden L Gross; Silas P Norman; Dorry L Segev; Mara McAdams-DeMarco Journal: Transplantation Date: 2019-07 Impact factor: 4.939
Authors: Christine E Haugen; Nadia M Chu; Hao Ying; Fatima Warsame; Courtenay M Holscher; Niraj M Desai; Miranda R Jones; Silas P Norman; Daniel C Brennan; Jacqueline Garonzik-Wang; Jeremy D Walston; Adam W Bingaman; Dorry L Segev; Mara McAdams-DeMarco Journal: Clin J Am Soc Nephrol Date: 2019-03-19 Impact factor: 8.237
Authors: Nadia M Chu; Xiaomeng Chen; Silas P Norman; Jessica Fitzpatrick; Stephen M Sozio; Bernard G Jaar; Alena Frey; Michelle M Estrella; Qian-Li Xue; Rulan S Parekh; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2020-07-08 Impact factor: 3.754
Authors: Nadia M Chu; Arlinda Deng; Hao Ying; Christine E Haugen; Jacqueline M Garonzik Wang; Dorry L Segev; Mara A McAdams-DeMarco Journal: Transplantation Date: 2019-08 Impact factor: 4.939
Authors: Elizabeth C Lorenz; LaTonya J Hickson; Renee M Weatherly; Karin L Thompson; Heidi A Walker; Judy M Rasmussen; Tara L Stewart; James K Garrett; Hatem Amer; Cassie C Kennedy Journal: Clin Transplant Date: 2020-07-24 Impact factor: 2.863
Authors: Kristen Sgambat; Matthew B Matheson; Stephen R Hooper; Bradley Warady; Susan Furth; Asha Moudgil Journal: Pediatr Nephrol Date: 2019-08-02 Impact factor: 3.714